INNOVATE BIOPHARMACEUTICALS, INC. Business Finance Contracts & Agreements
53 Contracts & Agreements
- Exchange Agreements (2 contracts)
- Forbearance Agreements (3)
- Note Agreements (10)
- Purchase Agreements (9)
- Registration Rights Agreements (4)
- Share Agreements (2)
- Stock Agreements (4)
- Underwriting Agreements (3)
- Warrant Agreements (16)
- Amendment No. 2 to the Forbearance Agreement (Filed With SEC on July 18, 2023)
- Amendment No. 1 to the Forbearance Agreement, dated May 18, 2023 (Filed With SEC on May 19, 2023)
- Forbearance Agreement, dated April 26, 2023 (Filed With SEC on April 27, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on March 15, 2023)
- Form of Placement Agent Warrant (Filed With SEC on March 15, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on March 15, 2023)
- Form of Common Warrant (Filed With SEC on March 15, 2023)
- First Amendment to the Amended and Restated Senior Secured Convertible Note Due 2025 (Filed With SEC on January 13, 2023)
- Form of Amended and Restated Senior Secured Convertible Note (Filed With SEC on November 8, 2022)
- Form of Senior Secured Convertible Note (Filed With SEC on June 30, 2022)
- Form of Securities Purchase Agreement (Filed With SEC on June 30, 2022)
- Form of 9 Meters Biopharma, Inc. Notice of Stock Option Grant and Award Agreement (Filed With SEC on June 22, 2022)
- Asset Purchase Agreement between 9 Meters Biopharma, Inc. and Lobesity, LLC, dated July 19, 2021 (Filed With SEC on November 15, 2021)
- Underwriting Agreement, dated March 30, 2021, by and between 9 Meters Biopharma, Inc., Citigroup Global Markets Inc., William Blair & Company, L.L.C., and Truist Securities, Inc (Filed With SEC on April 5, 2021)
- Underwriting Agreement, dated December 11, 2020, by and between 9 Meters Biopharma, Inc., William Blair & Company, L.L.C., and Truist Securities, Inc., as representatives of the... (Filed With SEC on December 15, 2020)
- Registration Rights Agreement, dated April 29, 2020, between Innovate Biopharmaceuticals, Inc. and the investors named therein (Filed With SEC on May 4, 2020)
- Securities Purchase Agreement, dated April 29, 2020, between Innovate Biopharmaceuticals, Inc. and the investors named therein (Filed With SEC on May 4, 2020)
- Form of Series A Convertible Preferred Stock Warrant (Filed With SEC on May 4, 2020)
- Form of Amendment to Short-term Common Stock Purchase Warrant, dated February 6, 2020 (Filed With SEC on February 12, 2020)
- Note Purchase Agreement, dated January 10, 2020, by and between the Company and Atlas Sciences, LLC (Filed With SEC on January 10, 2020)
- Note issued to Atlas Sciences, LLC (Filed With SEC on January 10, 2020)
- Form of Exchange Agreement (Filed With SEC on December 20, 2019)
- Form of Securities Purchase Agreement, dated April 29, 2019, by and among the Company and the purchasers party thereto (Filed With SEC on May 1, 2019)
- Form of Placement Agent Warrant (Filed With SEC on May 1, 2019)
- Form of Warrant (Filed With SEC on May 1, 2019)
- Amendment, dated April 25, 2019, to Securities Purchase Agreement, dated as of March 17, 2019, by and between the Company and the Purchasers party thereto (Filed With SEC on April 26, 2019)
- Form of Long-Term Warrant (included in Exhibit 10.1) (Filed With SEC on March 18, 2019)
- Note Purchase Agreement, dated March 8, 2019, by and between the Company and Atlas Sciences, LLC (Filed With SEC on March 13, 2019)
- Note issued to Atlas Sciences, LLC (Filed With SEC on March 13, 2019)
- Option to Purchase Senior Convertible Note, by and between the Company and Gustavia Capital Partners LLC and/or its affiliates dated as of January 7, 2019 (Filed With SEC on January 11, 2019)
- Common Stock Sales Agreement by and among the Company and H.C. Wainwright & Co., LLC and Ladenburg Thalmann & Co. Inc. dated as of October 26, 2018 (Filed With SEC on October 29, 2018)
- Senior Convertible Note with Gustavia Capital Partners LLC (Filed With SEC on October 5, 2018)
- Amendment and Exchange Agreement by and between the Company and Gustavia Capital Partners LLC, dated as of October 4, 2018 (Filed With SEC on October 5, 2018)
- Asset Purchase Agreement, dated December 23, 2014, between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Repligen Corporation (Filed With SEC on March 14, 2018)
- Form of Share Certificate (Filed With SEC on March 14, 2018)
- Senior Note dated January 29, 2018 (Filed With SEC on February 2, 2018)
- Form of Warrant (Filed With SEC on February 2, 2018)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 31, 2017)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on February 13, 2017)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 28, 2016)
